Us Congress 2025-2026 Regular Session

Us Congress Senate 2025 Bills & Legislation (Page 88)

US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB26

Introduced
1/7/25  
This bill excludes locality-based comparability payments from the calculation of retirement and disability annuities for new employees in the Federal Employees’ Retirement System. (General schedule and certain other federal employees receive locality-based comparability payments when their official worksite is located in a geographic area with a pay disparity between federal and non-federal workers of more than 5%.)
US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB260

Introduced
1/27/25  
Refer
1/27/25  
Report Pass
2/5/25  
Bottles and Breastfeeding Equipment Screening Enhancement Act
US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB261

Introduced
1/27/25  
Halt All United States Investments in Venezuela’s Energy Sector Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB262

Introduced
1/27/25  
Master Sergeant Roddie Edmonds Congressional Gold Medal Act This bill provides for the posthumous award of a Congressional Gold Medal to Roddie Edmonds in recognition of his achievements and heroic actions during World War II.
US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB263

Introduced
1/27/25  
FAIR Act of 2025 Fifth Amendment Integrity Restoration Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB264

Introduced
1/28/25  
Improving Veterans’ Experience Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB265

Introduced
1/28/25  
Freedom from Government Surveys Act
US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB266

Introduced
1/28/25  
Dr. Lorna Breen Health Care Provider Protection Reauthorization Act
US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB267

Introduced
1/28/25  
Restoring Access to Mountain Homes Act
US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB268

Introduced
1/28/25  
Saving American Workers’ Benefits Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB269

Introduced
1/28/25  
Ending Improper Payments to Deceased People Act
US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB27

Introduced
1/7/25  
Federal Employee Return to Work Act
US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB270

Introduced
1/28/25  
Natural Disaster Resilience and Recovery Accountability Act
US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB271

Introduced
1/28/25  
Stop Illegal Reentry Act
US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB272

Introduced
1/28/25  
Protect Infant Formula from Contamination ActThis bill imposes certain new requirements on infant formula manufacturers and the Food and Drug Administration (FDA) following the discovery of contaminated, adulterated, or misbranded infant formula. Specifically, the bill requires infant formula manufacturers to report to the FDA within one business day of learning that formula that was processed by the manufacturer but that is no longer within the manufacturer’s control may not provide required nutrients or may be otherwise adulterated or misbranded. Further, if any testing of finished infant formula reveals the presence of specified microorganisms (e.g., salmonella), the manufacturer must notify the FDA within one business day. (Under current law, manufacturers are only required to report contamination to the FDA if the affected formula has left the manufacturer’s control.) The manufacturer must also promptly provide the test results to the FDA and consult with the FDA on proper isolation and disposal of the affected product. The FDA must respond to such a notification and begin discussing proper investigative and corrective action with the manufacturer within one business day. Within 90 days of a report of adulterated, misbranded, or contaminated infant formula, the FDA must determine whether the manufacturer that reported the problem has performed, or is performing, appropriate investigative and corrective action. Finally, the FDA is required to periodically report on the infant formula supply chain and efforts to improve the safety and supply of infant formula, and must consult with other federal agencies and infant formula stakeholders on these issues.  

Research Filters

States
Terms / Sessions
Chamber Records